CX3CL1 and non-small cell lung carcinoma: Exogenous CX3CL1 reverses the effect of ADAR1 deficiency on increased NSCLC/AR cell sensitivity to Anlotinib (Wu et al., 2022), implying that ADAR1–CX3CL1 axis promotes Anlotinib resistance (Fig. 5E).